Granulocyte Colony-Stimulating Factor for Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study of Iranian Patients
Journal of Clinical Neurology
;
: 164-171, 2015.
Article
in English
| WPRIM
| ID: wpr-186077
ABSTRACT
BACKGROUND AND PURPOSE:
The aim of this study was to determine the efficacy and tolerability of granulocyte colony-stimulating factor (G-CSF) in subjects with amyotrophic lateral sclerosis (ALS).METHODS:
Forty subjects with ALS were randomly assigned to two groups, which received either subcutaneous G-CSF (5 microg/kg/q12h) or placebo for 5 days. The subjects were then followed up for 3 months using the ALS Functional Rating Scale-Revised (ALSFRS-R), manual muscle testing, ALS Assessment Questionnaire-40, and nerve conduction studies. CD34+/CD133+ cell count and monocyte chemoattractant protein-1 (MCP-1) levels were evaluated at baseline.RESULTS:
The rate of disease progression did not differ significantly between the two groups. The reduction in ALSFRS-R scores was greater in female subjects in the G-CSF group than in their counterparts in the placebo group. There was a trend toward a positive correlation between baseline CSF MCP-1 levels and the change in ALSFRS-R scores in both groups (Spearman's rho=0.370, p=0.070).CONCLUSIONS:
With the protocol implemented in this study, G-CSF is not a promising option for the treatment of ALS. Furthermore, it may accelerate disease progression in females.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Cell Count
/
Granulocyte Colony-Stimulating Factor
/
Disease Progression
/
Chemokine CCL2
/
Amyotrophic Lateral Sclerosis
/
Neural Conduction
Type of study:
Controlled clinical trial
/
Practice guideline
Limits:
Female
/
Humans
Language:
English
Journal:
Journal of Clinical Neurology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS